Department of Oncology, Hospital Costa del Sol, Marbella, Spain.
Head Neck. 2011 Jun;33(6):808-16. doi: 10.1002/hed.21551. Epub 2010 Oct 21.
Vascular endothelial growth factor (VEGF) expression seems to be associated with worse overall survival in patients with head and neck squamous cell carcinoma. The purposes of this study were to assess the prognostic values of the immunohistochemical expression of VEGF and vascular endothelial growth factor receptor-2 (VEGFR-2) in a cohort of patients with operable advanced laryngeal cancer who had been treated with induction chemotherapy.
VEGF and VEGFR-2 expression in the malignant cells was quantified by an enzyme immunosorbent assay in a retrospective series.
Fifty-nine patients were included in this study. We found moderate to high VEGF expression in 61% of patients and none to low expression in 39%. VEGFR-2 expression was moderate to high in 58% of patients and was none to low in 42%. The probability of a complete response to induction chemotherapy was significantly higher in patients with none to low VEGF expression (74% vs 40%; p = .02).
VEGF expression seems to be a significant predictor of complete response to induction chemotherapy.
血管内皮生长因子 (VEGF) 的表达似乎与头颈部鳞状细胞癌患者的总生存预后较差相关。本研究的目的是评估血管内皮生长因子受体-2 (VEGFR-2) 的免疫组织化学表达在接受诱导化疗的可手术晚期喉癌患者队列中的预后价值。
通过酶联免疫吸附试验对恶性细胞中的 VEGF 和 VEGFR-2 表达进行定量分析。
本研究共纳入 59 例患者。我们发现 61%的患者存在中到高强度的 VEGF 表达，而 39%的患者存在低表达。58%的患者存在中到高强度的 VEGFR-2 表达，而 42%的患者存在低表达。无到低 VEGF 表达患者对诱导化疗完全缓解的概率显著更高（74% vs 40%；p =.02）。
VEGF 表达似乎是诱导化疗完全缓解的一个重要预测指标。
